Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer

André Wendindondé Nana, Yu Tang Chin, Chi Yu Lin, Yih Ho, James A. Bennett, Ya Jung Shih, Yi Ru Chen, Chun A. Changou, Jens Z. Pedersen, Sandra Incerpi, Leroy F. Liu, Jacqueline Whang-Peng, Earl Fu, Wen Shan Li, Shaker A. Mousa, Hung Yun Lin, Paul J. Davis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The molecular pathogenesis of colorectal cancer encompasses the activation of several oncogenic signaling pathways that include the Wnt/β-catenin pathway and the overexpression of high mobility group protein A2 (HMGA2). Resveratrol - the polyphenolic phytoalexin - binds to integrin αvβ3 to induce apoptosis in cancer cells via cyclooxygenase 2 (COX-2) nuclear accumulation and p53-dependent apoptosis. Tetraiodothyroacetic acid (tetrac) is a de-aminated derivative of l-thyroxine (T4), which - in contrast to the parental hormone - impairs cancer cell proliferation. In the current study, we found that tetrac promoted resveratrol-induced anti-proliferation in colon cancer cell lines, in primary cultures of colon cancer cells, and in vivo. The mechanisms implicated in this action involved the downregulation of nuclear β-catenin and HMGA2, which are capable of compromising resveratrol-induced COX-2 nuclear translocation. Silencing of either β-catenin or HMGA2 promoted resveratrol-induced anti-proliferation and COX-2 nuclear accumulation which is essential for integrin αvβ3-mediatedresveratrol- induced apoptosis in cancer cells. Concurrently, tetrac enhanced nuclear abundance of chibby family member 1, the nuclear β-catenin antagonist, which may further compromise the nuclear β-catenin-dependent gene expression and proliferation. Taken together, these results suggest that tetrac targets β-catenin and HMGA2 to promote resveratrol-induced-anti-proliferation in colon cancers, highlighting its potential in anti-cancer combination therapy.

Original languageEnglish
Pages (from-to)279-293
Number of pages15
JournalEndocrine-Related Cancer
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

High Mobility Group Proteins
Catenins
varespladib methyl
Colonic Neoplasms
Down-Regulation
Cyclooxygenase 2
Apoptosis
Integrins
Neoplasms
Wnt Signaling Pathway
Thyroxine
tetraiodothyroacetic acid
resveratrol
Colorectal Neoplasms
Cell Proliferation
Hormones
Gene Expression
Cell Line

Keywords

  • Colorectal cancers
  • HMGA2
  • Resveratrol
  • Tetraiodothyroacetic acid
  • β-catenin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Nana, A. W., Chin, Y. T., Lin, C. Y., Ho, Y., Bennett, J. A., Shih, Y. J., ... Davis, P. J. (2018). Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer. Endocrine-Related Cancer, 25(3), 279-293. https://doi.org/10.1530/ERC-17-0450

Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer. / Nana, André Wendindondé; Chin, Yu Tang; Lin, Chi Yu; Ho, Yih; Bennett, James A.; Shih, Ya Jung; Chen, Yi Ru; Changou, Chun A.; Pedersen, Jens Z.; Incerpi, Sandra; Liu, Leroy F.; Whang-Peng, Jacqueline; Fu, Earl; Li, Wen Shan; Mousa, Shaker A.; Lin, Hung Yun; Davis, Paul J.

In: Endocrine-Related Cancer, Vol. 25, No. 3, 01.03.2018, p. 279-293.

Research output: Contribution to journalArticle

Nana, AW, Chin, YT, Lin, CY, Ho, Y, Bennett, JA, Shih, YJ, Chen, YR, Changou, CA, Pedersen, JZ, Incerpi, S, Liu, LF, Whang-Peng, J, Fu, E, Li, WS, Mousa, SA, Lin, HY & Davis, PJ 2018, 'Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer', Endocrine-Related Cancer, vol. 25, no. 3, pp. 279-293. https://doi.org/10.1530/ERC-17-0450
Nana, André Wendindondé ; Chin, Yu Tang ; Lin, Chi Yu ; Ho, Yih ; Bennett, James A. ; Shih, Ya Jung ; Chen, Yi Ru ; Changou, Chun A. ; Pedersen, Jens Z. ; Incerpi, Sandra ; Liu, Leroy F. ; Whang-Peng, Jacqueline ; Fu, Earl ; Li, Wen Shan ; Mousa, Shaker A. ; Lin, Hung Yun ; Davis, Paul J. / Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer. In: Endocrine-Related Cancer. 2018 ; Vol. 25, No. 3. pp. 279-293.
@article{e11055e5e97f478ba77bd6714abbc2bb,
title = "Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer",
abstract = "The molecular pathogenesis of colorectal cancer encompasses the activation of several oncogenic signaling pathways that include the Wnt/β-catenin pathway and the overexpression of high mobility group protein A2 (HMGA2). Resveratrol - the polyphenolic phytoalexin - binds to integrin αvβ3 to induce apoptosis in cancer cells via cyclooxygenase 2 (COX-2) nuclear accumulation and p53-dependent apoptosis. Tetraiodothyroacetic acid (tetrac) is a de-aminated derivative of l-thyroxine (T4), which - in contrast to the parental hormone - impairs cancer cell proliferation. In the current study, we found that tetrac promoted resveratrol-induced anti-proliferation in colon cancer cell lines, in primary cultures of colon cancer cells, and in vivo. The mechanisms implicated in this action involved the downregulation of nuclear β-catenin and HMGA2, which are capable of compromising resveratrol-induced COX-2 nuclear translocation. Silencing of either β-catenin or HMGA2 promoted resveratrol-induced anti-proliferation and COX-2 nuclear accumulation which is essential for integrin αvβ3-mediatedresveratrol- induced apoptosis in cancer cells. Concurrently, tetrac enhanced nuclear abundance of chibby family member 1, the nuclear β-catenin antagonist, which may further compromise the nuclear β-catenin-dependent gene expression and proliferation. Taken together, these results suggest that tetrac targets β-catenin and HMGA2 to promote resveratrol-induced-anti-proliferation in colon cancers, highlighting its potential in anti-cancer combination therapy.",
keywords = "Colorectal cancers, HMGA2, Resveratrol, Tetraiodothyroacetic acid, β-catenin",
author = "Nana, {Andr{\'e} Wendindond{\'e}} and Chin, {Yu Tang} and Lin, {Chi Yu} and Yih Ho and Bennett, {James A.} and Shih, {Ya Jung} and Chen, {Yi Ru} and Changou, {Chun A.} and Pedersen, {Jens Z.} and Sandra Incerpi and Liu, {Leroy F.} and Jacqueline Whang-Peng and Earl Fu and Li, {Wen Shan} and Mousa, {Shaker A.} and Lin, {Hung Yun} and Davis, {Paul J.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1530/ERC-17-0450",
language = "English",
volume = "25",
pages = "279--293",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer

AU - Nana, André Wendindondé

AU - Chin, Yu Tang

AU - Lin, Chi Yu

AU - Ho, Yih

AU - Bennett, James A.

AU - Shih, Ya Jung

AU - Chen, Yi Ru

AU - Changou, Chun A.

AU - Pedersen, Jens Z.

AU - Incerpi, Sandra

AU - Liu, Leroy F.

AU - Whang-Peng, Jacqueline

AU - Fu, Earl

AU - Li, Wen Shan

AU - Mousa, Shaker A.

AU - Lin, Hung Yun

AU - Davis, Paul J.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The molecular pathogenesis of colorectal cancer encompasses the activation of several oncogenic signaling pathways that include the Wnt/β-catenin pathway and the overexpression of high mobility group protein A2 (HMGA2). Resveratrol - the polyphenolic phytoalexin - binds to integrin αvβ3 to induce apoptosis in cancer cells via cyclooxygenase 2 (COX-2) nuclear accumulation and p53-dependent apoptosis. Tetraiodothyroacetic acid (tetrac) is a de-aminated derivative of l-thyroxine (T4), which - in contrast to the parental hormone - impairs cancer cell proliferation. In the current study, we found that tetrac promoted resveratrol-induced anti-proliferation in colon cancer cell lines, in primary cultures of colon cancer cells, and in vivo. The mechanisms implicated in this action involved the downregulation of nuclear β-catenin and HMGA2, which are capable of compromising resveratrol-induced COX-2 nuclear translocation. Silencing of either β-catenin or HMGA2 promoted resveratrol-induced anti-proliferation and COX-2 nuclear accumulation which is essential for integrin αvβ3-mediatedresveratrol- induced apoptosis in cancer cells. Concurrently, tetrac enhanced nuclear abundance of chibby family member 1, the nuclear β-catenin antagonist, which may further compromise the nuclear β-catenin-dependent gene expression and proliferation. Taken together, these results suggest that tetrac targets β-catenin and HMGA2 to promote resveratrol-induced-anti-proliferation in colon cancers, highlighting its potential in anti-cancer combination therapy.

AB - The molecular pathogenesis of colorectal cancer encompasses the activation of several oncogenic signaling pathways that include the Wnt/β-catenin pathway and the overexpression of high mobility group protein A2 (HMGA2). Resveratrol - the polyphenolic phytoalexin - binds to integrin αvβ3 to induce apoptosis in cancer cells via cyclooxygenase 2 (COX-2) nuclear accumulation and p53-dependent apoptosis. Tetraiodothyroacetic acid (tetrac) is a de-aminated derivative of l-thyroxine (T4), which - in contrast to the parental hormone - impairs cancer cell proliferation. In the current study, we found that tetrac promoted resveratrol-induced anti-proliferation in colon cancer cell lines, in primary cultures of colon cancer cells, and in vivo. The mechanisms implicated in this action involved the downregulation of nuclear β-catenin and HMGA2, which are capable of compromising resveratrol-induced COX-2 nuclear translocation. Silencing of either β-catenin or HMGA2 promoted resveratrol-induced anti-proliferation and COX-2 nuclear accumulation which is essential for integrin αvβ3-mediatedresveratrol- induced apoptosis in cancer cells. Concurrently, tetrac enhanced nuclear abundance of chibby family member 1, the nuclear β-catenin antagonist, which may further compromise the nuclear β-catenin-dependent gene expression and proliferation. Taken together, these results suggest that tetrac targets β-catenin and HMGA2 to promote resveratrol-induced-anti-proliferation in colon cancers, highlighting its potential in anti-cancer combination therapy.

KW - Colorectal cancers

KW - HMGA2

KW - Resveratrol

KW - Tetraiodothyroacetic acid

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=85042584220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042584220&partnerID=8YFLogxK

U2 - 10.1530/ERC-17-0450

DO - 10.1530/ERC-17-0450

M3 - Article

C2 - 29255096

AN - SCOPUS:85042584220

VL - 25

SP - 279

EP - 293

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 3

ER -